Coverage
-
June 23, 2026
A New York federal judge preliminarily approved a $7 million deal resolving class action claims alleging Spectrum Pharmaceuticals Inc. overstated its regulatory prospects for winning approval for a cancer treatment.
4 other articles on this case.
View all »